NPCE - Earnings call transcript Q2 2024

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good afternoon, and welcome to NeuroPace's Second Quarter 2024 Earnings Call. [Operator Instructions] As a reminder, this conference is being recorded. I would now like to turn the conference over to your host, Jeremy Feffer from LifeSci Advisors. Please go ahead, sir.

Jeremy Feffer

Good afternoon. Thank you for joining us for NeuroPace's second quarter 2024 financial and operating results conference call. will Kuhn, Joel Chief we Officer; Chief call, Rebecca and Financial today's hear Becker, from Executive On Officer. Earlier for today, XXXX. the results second quarter NeuroPace ended June released financial XX, company's release available press the of neuropace.com. copy on A the website at is

statements this safe remind laws, we this that pursuant which that forward-looking are forward-looking call, during events that market our clinical relating on that Act various events, those these of forward-looking are of Before meaning Accordingly, expectations XXXX. Any predictions performance, the relate the statements, the projections, Private assumptions. These statements throughout Litigation or conditions, statements and place make those made actual current and made you market to within like you implied these should financial future growth and expansion, materially undue operating harbor and Securities results forward-looking will management, of I Reform market from would to statements and to or results estimates include statements. including expense call begin, by statements. statements. of based not estimates of future forecasted opportunity provisions NeuroPace's performance uncertainties those trials cause opportunities, around business to we are Federal revenue could trends to on differ securities reliance involve All and material risks commercial or

we filed for with ended the Report Form XXXX, XXXX, uncertainties intention is believe be Annual section June contains detailed XXXX. with XX-Q any recent conference that with the business, more August Form we including XXXX, information, this for live broadcast required or of of except with For filings associated in on with refer law, SEC time-sensitive future the over the on by our public December X, or which Quarterly SEC, to quarter with Officer, Report accurate on year on as and the of and reports filed SEC risks Risk and disclaims XX-K XX, to our other events projections the only future. This financial obligation, NeuroPace's the to please the SEC our Factors file descriptions XX, the ended any now call our March call as may Joel? Joel the Chief statements, new otherwise. And information, of Becker. that, Executive update or whether I turn revise to because will any or NeuroPace XX, forward-looking

Joel Becker

half good I our insights for off key start as will and before Jeremy, to by well by quarter you, the of everyone. reviewing our as second Kuhn performance in followed details will offering the to over financial XXXX, our which CFO, be present second performance afternoon, turning call session. business June the ended [ Thank XX, XXXX, today's for additional Rebecca Q&A the a quarter priorities call ] our the of around

Let's get started.

We to are as pleased gross strategy. our and execute team's growth, the revenue management of against multiphase demonstrating XXXX, in expense operating second the expansion we quarter with margin growth continue performance

last RNS enrollment benefited the the the quarter impressive that total a same System RNS of growth consider of reported up from DIXI $XX.X we basis our if revenue the second XX% SEEG and XXXX, on the biotechnology System. RNS of from For of more products Medical compared sales contribution the year. quarter of the even year-over-year growth growth results majority to period from in contributions a quarter year-over-year and the the strategic from million, study. with included collaboration, in coming NAUTILUS XXXX was for the sales sales Revenue sales small of second we

NAUTILUS growth contributions XXXX Excluding in QX of last was units the in RNS year, sales study from XX%. from of QX

our access of X-part expand to is ahead expanding, and look by adoption we executing as growth the strategy System focus Our to utilization. RNS

to performance existing of part prescribers first Level and number to Systems drive of And QX adoption. of strategy, this greater X driven in by increasing epileptologists number new centers utilization was adoption and the during XXXX. working Our RNS RNS with on expand focus centers. second our we primarily a This the training to record continue the of of at levels quarter includes

centers. As have Level $X over such, a is significant patients within for reminder, within as opportunities drug-resistant to centers the to annual epilepsy we and be market opportunity billion, X grow estimated these

program. continued also CARE RNS second access of expanding long-term call to phase which the to strategy We we the of our X outside centers, growth on make therapy Project progress Level

We early the are tracking of an are with patient program. the is number the we of the associated pilot currently program encouraging and phase in metric that referrals

of commercial their we an social which territories supporting in to education the sales expansion pilot the the on commercial implants. as newly contracting to in efforts. These the have expansion impact experiencing also peer-to-peer number X CARE include geographies hired we program accompanied be lines. product begun RNS been sales and are media and on X and RNS our RNS primarily have centers such we placement commercial our into and these such new fully from are regard representatives additional their representatives are and target show referrals referrals contributing candidates. Activities identified sign Level activities, of activities activities opportunities now see to have to DIXI I'm to symposia good in positive our centers the and We geographies. With increasing where announce webinars, revenue of consider We around and pleased that along more Level of our center the focused begin as in training independent completed where outside growth sales will a of have initiation geographies programs, organization, This representatives awareness therapy generating higher sales of broader for centers, is as with by physicians educating patients professional they having the awareness programs. program digital

going the about are We make our business to excited contributions will forward. they

our complete the trial in study, patient growth follow-up on third the currently which is System. RNS this approved for all strategy This implants for expanding Idiopathic NAUTILUS of strong focused is RNS that of interest pivotal are drug-resistant based effort indications significant Epilepsy. Finally, and phase the is the that the the patients the the study with unmet evidence exists Generalized phase. We further is need in in on believe

of be generalized on the first complete track for study As to post primary and XX represent epilepsy. is a device expansion the System reminder, X-year XXXX. potential opportunity a requires first This our an effectiveness highly FDA-approved to an in the the RNS indication the implant. If quarter evaluation of endpoint market evaluation NAUTILUS trial safety has meaningful would months a with and approved, follow-up

to which the had team exclusive see is an for RNS DIXI our to highly This the to success to we addition CECs. System, Medical physicians revenue team market and diagnostic electrodes to with products has offering Systems, and growth partnership complementary our our RNS additional sell our from In opportunity a with related our also commercial provides their sales epilepsy. call continue with on at

of review let among collaboration that System the progress, and which of provide reporting their identification providing for strategic this is used to support, with the is our overview insights ability readiness Lastly, we fourth its as treatment example Phase criteria and analyze financial me an the another turn analysis. We to quarter Rebecca groundbreaking call help inform that satisfying quarter which are the over XXXX. related can to other through operational we RNS data, company our potential the of biotechnology Xa System trial, of of a Rebecca? second the remain through value data, to pleased then results we proven with including, our entered clinical patients generate believe that can into clinical collect enrollment in XXXX things, strategies. With now to and services trial collaboration RNS

Rebecca Kuhn

growth of Thank you, for second system. growth million second of our the quarter the $XX.X Joel. was increased XX% of to for by revenue quarter This XXXX $XX.X RNS was primarily sales of representing compared NeuroPace's driven XXXX. million,

with was in was revenue increase year XX.X% changes, the as also increase of second an gross funding. SG&A expenses was second development offset volume expense result of improvement by over were increase Medical operating an costs marketing XXXX. the by increase more million in $XX.X XXXX offset in expenses prior personnel-related XXXX the sales due growth in in offset to sales second XX.X% expenses on lower the in $XX.X growing expenses cash. XXXX. growth XX% This margin personnel-related with in meaningful increase our primarily primarily from in also million of due in in to the for expenses. Total the manufacturing effectively was the With clinical quarter and increase leverage $XX.X quarter partially in our by and studies, second partially units. and gross Medical of the in quarter product an of decrease margin, margin in representing fixed while from demonstrated $XX.X $X.X revenue same largely compared quarter prior driven products. R&D of This DIXI our by partially revenue million compared the same of of spread X%. personnel resulting for a period and an grant We to of due managing expenses This only DIXI decrease as was $X.X margin was compared overhead overall distribution XXXX for expense quarter, in an million to the from focus quarter in second increase million of of increase was were an by XXXX period million the operating growth, strong with driving we generated the year, gross compared products. Gross operating The period. RNS

was interest million quarter remainder focus $X.X recorded the of objectives, with in year quarter of continue period. quarter continue prior in we XXXX of of with Net of quarter million in on compared of second XXXX. the expect in XXXX to these operations expense second period. the million prior which We from We the million loss year compared second through balancing to XXXX. Loss for $X.X XXXX $X.X to $X.X million second the was $X.X million the compared in $X.X the

As disciplined in in million $X strategy, to the we resulting compared discussed management in $X.X have second cash quarter of burn maintained previously, a million XXXX. second quarter XXXX of expense of the

million. XX, Our cash of was short-term and balance $XX.X investments June as XXXX,

of as million Our $XX XX, long-term June totaled XXXX. borrowings

As a debt maturity final our of is XX, XXXX. September reminder, the

of to with Replacement of consistent in relatively implant compared in DIXI range revenue RNS $XX expect Regarding annual increase growth of is million to million, be guidance in total to This XX%. $XX XX% revenue our an now be XXXX Medical System, from approximately mostly meaningful expected with to continuing a we products be to increase growth sales to XXXX, make by our for the driven the an contribution. of sales expected is XXXX.

our revenue expect margin revenue although for and variability We a XXXX, fluctuations overall factors. other in the to XX% of to in we be XX% DIXI gross to see to proportion may small range due Medical of

for expect million XXXX the turn We would million, to for range call now expenses in noncash Joel? over Joel million between $XX to operating and stock-based closing compensation back approximately to remarks. and $XX like expense. I including $XX

Joel Becker

Rebecca. you, Thank

are with contributing announce growth management quarter. meaningful quarter cash of expansion gross all margin the in to discipline, operating coupled revenue We second excited another demonstration solid of to strong the expense and

we of now concludes close over our on would look patients, to updating epilepsy on treatment progress operator, forward the questions. the you of progress to RNS XXXX. This call help to who remarks. prepared drug-resistant Additionally, continuing the I open for our make the of the access to will call I our through for the Operator? half to expanding to like are gap second and execution therapy strategy turn

Operator

from Chopra [Operator Instructions] The first comes Fargo. Wells have Vik of question we

Vikramjeet Chopra

nice couple on Congratulations me. a quarter. for questions of A

number some Maybe us this can number please. So are coming information Project follow-up, more on cadence you just from? an about a you increasing referred on And referrals I any of who the color to had or And just talk then or CARE, the if share? you these other referrals. the of give could

Joel Becker

centers. referral as implants pipeline your CARE, have we seen the question. as the in for the of activity you targeted of really side, beginning both well, interest now on these and Thank increasing well as as interestingly patients well development the Yes, of and in a

we've a while secondly may II education might in at able in who patients identify what just cetera. And evaluate who et a therapy, referring RNS there patient a started, as populations that they're programs is may the they they underway awareness patients Level potential they back comfortable previously that look getting in. and well who patient different their candidates patients initial running, see we are centers treated feel set then that eventually may Level be community get center as testing, couldn't while as referred specifically to to as their referral but their get more -- center those into up, training with X out and well, because the for setting, either they So and up good get in side, be community patients seen wouldn't to setting, more we generate are uncovered, or a for have X referral be traditional have for Phase been people on

here, well And candidates, of our as an well in here on focus therapy activity that referrals, both there led has a as with in of efforts RNS be awareness recent role the and as quarter. described training and so, can education to us implants the level and I've the as somebody's identification play might have technology as good increasing around patients practice

Vikramjeet Chopra

top then we you margin the us ] ] think help on margins year? the the of and line And OpEx half the OpEx. line and about guidance, back Maybe should for [ held the understand raised cadence Okay. [ the just gross how cadence

Joel Becker

OpEx, start want us margin in? on I'll maybe to chime you and here Rebecca, Do out and

Rebecca Kuhn

Absolutely. OpEx Vik, kept you we noted, our and margin as consistent. Yes, Sure. gross guidance

$XX and see Our gross Generally, to half million, for regard the us course, can improvement, expect a over to fluctuate margin expenses, factors. that variety squarely was over quarter-to-quarter. With to but, guidance. see operating the RNS puts a variation we unexpected little improves gross it's volume, with first margin of our expect our not time, which -- small year to OpEx due within of we of

If annualize fluctuations the the see throughout year, expect in significant that, you of rest we don't OpEx. to

Meeting sometimes will major fourth say, our Although Annual medical some the in the see increases AES meeting, result December. I we quarter of a in as

Operator

Fitzgerald. we from Cantor Ross next have comes The question Osborn of

Ross Osborn

quarter. the on strong Congrats

by So it revised like strong the your maybe guidance, driven on QX. revenue most of looks it is

CARE there, would through growth kind utilization board, throughout continue between the coming diving So And why back ones by then guess, program? versus expect to on in of users existing you the I wouldn't with walk half? new you, that especially

Joel Becker

the thanks Ross, question. Yes. for

increased $XX it as take top a look So through XX% here, QX million, XX% guidance our $XX.X got guidance, first we from to we XX%, to as million, as at point And at we you range to we've $XX.X at end, million starting so the the QX mentioned. half. XX% raising

to got we've So is $XX.X second really million half, got guidance through in range the half. first million our we what and implies $XX $XX.X the million

we the But We seasonality -- back talked not of that do growth break range, by we've obviously, months. we're given have we out Now growth, the a about bit previously, I the in do and summer each half think that don't of little year in with and quarters. quarter. expect a as

million calendar. the the half implies do But signal so $XX or comps growth good the in half do that of guidance the growth looking recognize look second little the full second the a half there year, at well. the through of versus the guidance we as doesn't So in to see if a tougher year rate, We year, it hold you $XX increased recognizing rate first get the that from perspective. and growth of million are in

Ross Osborn

initiatives generalized that It's what then well. are for seeing next Understood. indication that some ahead of here the are expanded deck was it And Okay. NAUTILUS launch, 'XX expected year? is progressing nice on and key

Joel Becker

Yes.

that make you're great track the we excited it's there. continue proceeding and right, and So about NAUTILUS is a question. on to well we're And progress

pilot think length a CARE that's with program, focus significant of and Ross, us is, Some for for area meaningful as talked a the associated and is expansion one. we here, about I'd things and at well, opportunity the us Project we've point to number

[ for expand therapy outside ourselves well direct ability and RNS Level us up the to ] increasing set for of So centers X as potential as both referrals.

commercial been the incremental implementation just the that make, completion of making here hiring and investments quarter associated one, CARE So and our this program. Two, the we've continued to expanded training that organization. and and of announced now Project the and

both growth to further areas organization support well CARE going in most that. overlap Project got we've where then to we're really, as advantage divestments well take these investments our with so good programs and strong in it made we've And recent commercial as of amplify the previously the as to

service Level So that's for delivery a talked it's of expanding of X expanding indications. second site focus key we've area about, It's X-phase and utilization Project us. And It's it's also and within CARE, a then, right? adoption with increasing care strategy, centers. then

the talked Level Project it a hit what as patient about how and RNS we of the area you RNS us as story, utilization for that's which currently is NAUTILUS. the about adoption therapy the So modern scope big well centers. piece CARE so expanding, expanded third there of is already. And and and focus utilization, populations. increasing then broadening of people both I can within on adoption, use X is and within additional talk patients, indicated as

asked hybrid of patient the patients applications past technology well, including with surgical the and focal You've network epilepsy other in treatment -- focal as drug-resistant are of populations there about use the well. for as stimulation along the

the that. for up story both expanding Project for where then It's you how modern really organization of potential executing they our us and the the as populations, also trial telling we're folks therapy develops well expansion and our patient to work may and all things different be well and as may expanding it's investing to those people be, to and indications. This indication patients both then RNS then Level treated. into support adoption of expansion treated and that NAUTILUS increase as RNS commercial can as clear be eventual CARE X can the Project commercial use utilization and indications patient So within approved successful not centers. And the CARE on and a our and doing with now, assuming in be organization set expands

here So together these there. work things and between all

Operator

The from next Partners. we question Kratky that Mike have of Leerink comes

Michael Kratky

in NAUTILUS how year-over-year quarter? for this to Did sales you XX% quantify question from you out clarifying enrollment XQ start. growth backed you RNS One that get benefited that much to 'XX

Joel Becker

that strength trial not outside that, the point is said things and commentary and NAUTILUS breaking just that going what to quantify any trial the we broke that good that as we usage in provide there the program and of comment 'XX, we're it a we a line. Mike, start and have didn't about think NAUTILUS. But we wanted as can't any of off-label product obviously, folks revenue out way business. bullet as don't of an did just out by have the 'XX we reminder -- We a to point on of don't But -- note underlying to benefit the to is the we of was indicator reason we that -- a products by in the that excluding strength in indication in clinical a around

It's to demonstrate that reminder that, addition at of broken something point then growth had a was to that 'XX, So you period look in make and the up people 'XX, it we growth. current in have we really we to the as a in that included as out. was benefit had that

Michael Kratky

maybe and on the and have but learnings CARE really this overall on just of Got is part side? thinking early on building be Super of And there program on from efforts it's any of Maybe third helpful. which strategy I half? in could days, your separately, the recognize second here the Project fourth last just for year anything the it. the your from curious in quarter shaped you then commercial how that point, that the preliminary pilot

Joel Becker

as to I And us people that for the well as or potentially there with just patients well. that education be tee guess Yes. patients are and [ can as see regard to rather -- for treat important both there with own is what identifying what training regard to ] is with to centers refer regard I patients we the do, would that we've learned treated up to their things in here potential targeting, benefits -- the

expansion very both, go-forward opportunity I And strategy see we so mentioned, been a focal as continue CARE. And about all that's to there, the as drug-resistant as population significant current helpful think requirement think in we then we trial about the The testing. for as Phase refer a II isn't population. an successful well those a that Obviously, with patients again, pending that. potential, there for to for indication NAUTILUS

the more our community. this think So as well. we opportunity think are to as be learnings And here about even associated that with process presence during going in we helpful the

Operator

next we have question Instructions] comes of Markets. Takkinen [Operator from Street The Lake Frank Capital

Frank Takkinen

us a those that growth in level the can versus progress. the help established growth network. up a Congrats that X, bit us understand the coming commentary from follow the center kind of Anything per on quarter? Any on to which X really a color drove [ Level in at a lot little of on more better can prong around you growth of growing I utilization wanted prescriber? provide also new from X of a ] the center deep

Joel Becker

prescribers. And in in modern rate so they're utilization as people therapy increasing utilization, the us we the it's System do different is, thanks as for where utilization plank you adoption strategy kind here the we which focused a That's Level have adoption. our regard on Level there's about with question. RNS of we're and pieces And to established really RNS highlighted of focused prepared adoption, Frank, where focus really using our thinking driving the patients given really say, has are RNS inside the ] how number on prescribers utilization, which first And been. our of -- centers story, the X our expand great of for. of that been in And X your the both of X focused on, growing both here question. is the for that, really it. at of number expanding It's then, well kind [ here basis centers, the footprint, as comments, using what of as we is

we so seen And prescribers. success number in expanding have the of

that's been focal applications us. contributions I'd populations, guess have well. of expanding a network stimulation and those focal focus to out there. And utilization, And been something utilization call together, that seen key And treating impactful. And in with the of to seen progress growth of obviously as users. seen I for -- the -- use but move regard we've then, been they for good area treating prescriber the to RNS treating so, the populations we've there. network number good for also as particular, a We for system things deepen then that both And have new really work prescriber that working as getting quickly from to we've

So of work together, been. the where really X our closely focus pieces but that's it has

Frank Takkinen

Any maybe all, And don't had I know, learnings about there's asset benefit EEG taken to funnel. quantifiable at bag related time? having from in if any when improved to the [ obviously just the from ask implant, my to other DIXI. sense. now that partnership was makes for anything I RNS you second that's for ]? having patient if broader learnings first some When understanding you've That from the some Okay. or established, one, -- to DIXI there And then time hoping was was

Joel Becker

broader [ ] places get Frank, quantify in visibility we where say this where we going accounts are we're a that absolutely I But of at point, -- to specifically have as metric. that terms earlier are have there would better result, Nothing seen had diagnostic and would conversations at and and that. we can, to to about of in patients process group the a visibility where hadn't sooner than we if a have patients

visibility the number helped and has have had, to people a wouldn't of it may in and look places given accounts good tenured ] in we further as conversations maybe has a them [ part give especially and of us be quite helped upstream. broaden those have aren't that's upstream where So opportunity visibility we who

Operator

The have of comes Robbie from next question JPMorgan. Marcus we

Robert Marcus

the previous of implied half, to that's growth I and half I question a how Obviously, back that's to second normal second medtech for but the versus doing you're couple half work. first rate. A sort most seasonality the on more businesses me. circle in hear dollar-wise wanted

slowing could it in was just the hoping personnel dollar decelerating the rate you Just the So to helpful. Is rates, the more that Is due revisit to the the it it and amount, growth due market? ignoring Is help walk us would I reasons? us cut? through think a be growth conservatism? slowing about

Joel Becker

question, for the Thanks Robbie.

And so, made the to don't we market. would see don't just I a in as go earlier, we cuts back as I point see any any slowing it and really of it that result internally, and

business. we be We healthy demonstrating pipeline, invest have consider discipline, work then and as to we the seen well good the -- line to good to what operating and populations good in patient as we're in growing continue our in expense top but absolutely investing

are that comps the there expect we've associated do also back the is half we months, year. that look seasonality -- do of previously. the that that from seen year we expect there do you impact. We forward, the in in that some we don't summer So with anything see and tougher see get prior when And

going in we're the second We're the positioned to about where see the year. grow business of how to half the do grow to we're we again, So continue business and excited from we But of recognize the growth second been. a also some have us that do year perspective. comps affect and in rate the those year from harder get of last half

Robert Marcus

growth second half I'm versus XXXX. sitting rate well reason above is half that focused in the the The half first street on second because is Okay.

that sense new the move a is out get is better to can conservative I normal, approach trying I'm that, a going to very So 'XX? on. -- But

you I'll me. both. for ones quick X ask Just

gross remember even the margin, revenue a on and while. the lot that talked about sales DIXI for impact you in number You a a percent a I giving of and revenue us contribution for don't but or

] was up just be So X years? due if you DIXI? your thoughts when hoping I on debt in how maybe on then could it also us comes give us sync [ you could And you'll handling the

Joel Becker

don't at we waypoint, in. and the I'll we sales. by DIXI handhold Rebecca product there, of Robbie, But break to to line. of I'll regards provide ask XXXX, XX% then chime approximately off end of right, the start you're did total being the the our With up us revenue revenue DIXI,

an number $X.X couple think percentage total we've quarters was time, given we about we when DIXI update that the -- at update 'XX, end of was at I million referenced, the be from would of So that believe at I initiated it that from when relationship, given the revenue as we a you XX% that the so our revenue revenue. -- ago and of had

little flexibility obviously, flexibility well you bit a gives year additional maturity us debt of That debt way that the be to we the flexibility, we a is us to So September that gives a environment as by recently develop. debt, to continue the be us believe, the just It to lower out through interest there think should of going that. beneficial rate in help. With take as announced as able of XXXX. to the some manage It the gives we hopefully, potentially of a advantage extension well. regard gives

to ask either I'll if on, on comment anything those? want Rebecca there's So you one of

Rebecca Kuhn

well. covered you've it think pretty I

specifically for debt. discussed haven't We plans our

interest flexibility it be Joel for that, best shareholders' stretching interest. at and a will additional options stretching -- would result year, have final evaluate mentioned. And in we best continue continue and company's a as We the to our considering to we do what for maturity of as out the

well. covered Joel all actually, think it I pretty So

Operator

from comes Polark question Wolfe final Michael of Research. Our

Michael Polark

anything? and heard for I what ones. revenue made DIXI, remarks, a your Rebecca, I about you or you comment contribution it you said. mix quick if didn't across on you me said DIXI Can remind quarter. in the what means quite modeling what catch Two prepared

Rebecca Kuhn

didn't products. know, I that commented to impacted our to distributed as that said of greater many a DIXI. margin you gross RNS margin believe, our about DIXI anything has that. that's meaningful before we beyond for it. gross has contribution as We we favorable stated revenue made is regard really and factors. growth, With margin commented and But than or gross And DIXI, a really margin, we've our say course, -- before, gross a We've by

Joel Becker

that period, variability offered be relative of overall thing -- may that. of the in from gross the as to Rebecca context period The some DIXI Yes. might context we revenue margin fluctuations to outside mentioned, other the in have nothing discussion. but small due that to only the of just

Rebecca Kuhn

Yes.

Michael Polark

the you was on just quantified there's territory I just hiring me Can this much expansion of expanded there, the that, like recall clinical headcount, it comment. scale If in and appreciate any remind resources? it The training. this, I don't color All we've you follow-up right. Okay. I'd have was reps incremental terms it. of or -- quota-carrying or

Joel Becker

is we've there an expansion. what indicate talked very to it the expansion Mike, carefully focused. enough we characterized chose commercially that big is incremental just about as it's and [ it We ] consider we've -- that

your to it or we've incremental an characterized question resources, of is as focused support just and expansion. clinical So it commercial, commercially

enough So we we at that necessarily point. it's big headcount given quantified talking want about specific this but be it, to any haven't

Operator

back call remarks. like and Ladies to sir. turn gentlemen, have to Becker ahead, Please our Joel And I session. would closing reached question-and-answer the we go of for end the

Joel Becker

NeuroPace the Thank in progress and their everyone our both hard the for here our delivered and team your well about strategy, quarter about going of also attention as to for this forward you the remainder plans the work. We're excited year appreciation to for as quarter all you. the that beyond. of want We're Thank has time excited past everybody express for today. at and our

means We again. really all all strategy. very that Thanks you further business future and now on and positioned are growth us. on the We what to for it to to continue is in future And to look calls. that well X in phases updating execute forward of our the the of exciting for into

Operator

you then us. joining and Thank Ladies conference. today's that gentlemen, for you. concludes Thank

your You lines. may now disconnect

NeuroPace (NPCE) 13 Aug 242024 Q2 Earnings call transcript